Clinical Trials and New Drugs · us
enGene updates trial results for bladder cancer gene therapy detalimogene, plans to begin FDA submission by year-end
Among high-risk patients unresponsive to BCG treatment, 56% achieved a complete response at some point, but the complete response rate at 12 months was 24%. As follow-up data mature, this bladder-preserving therapy is moving toward a marketing application, with the durability of efficacy remaining a key focus for review.
For high-risk patients whose bladder cancer has not invaded the muscle layer but is unresponsive to bacillus Calmette–Guérin (BCG) treatment, controlling cancer and preserving the bladder are often simultaneous challenges. On November 11, enGene announced updated data from the Phase 2 LEGEND trial of its gene therapy detalimogene. Following a pre-submission meeting with the U.S. Food and Drug Administration (FDA), the company said it plans to begin submitting a biologics license application (BLA) before the end of 2026.
Detalimogene is an investigational nonviral gene therapy administered by intravesical instillation and designed to trigger a local antitumor immune response. This update comes from LEGEND’s pivotal first cohort, which enrolled 125 patients with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer, all of whom had carcinoma in situ, with or without papillary tumors. These patients need an opportunity to preserve their bladder while facing the risk of cancer recurrence or progression.
As of October 29, 2026, 56% of the 120 efficacy-evaluable patients had achieved a complete response at some point after treatment, up from 54% in the April analysis. However, having achieved a complete response at some point does not mean that the response is still maintained one year later: the complete response rate at the 12-month time point, calculated from 110 patients, was 24%, with a 95% confidence interval of 16% to 33%. These two figures answer different questions, and neither can be directly interpreted as a cure rate.
How long responses last was another focus of this follow-up. Median follow-up among responders increased from 9.2 months to 12 months, while median duration of response increased from 8.6 months to 10.1 months. A preliminary Kaplan–Meier estimate put the proportion of responses lasting at least 12 months at 43%. This analysis addresses response durability and differs from the complete response rate among all patients at 12 months. OncLive noted that 9 patients were still awaiting assessment for a response duration of at least 12 months, including 8 receiving maintenance treatment, so the estimate may still change.
At this data cutoff, 97% of efficacy-evaluable patients had not progressed to muscle-invasive or metastatic disease, and 86% had not undergone cystectomy. These results offer indications of disease control and organ preservation, but they are observations within the current follow-up period. They cannot establish an improvement in long-term survival or prove that receiving this therapy will prevent future surgery.
The safety analysis included 125 patients, of whom 59% experienced at least one treatment-related adverse event, mostly Grade 1 or Grade 2. Common symptoms included fatigue, painful urination, and urinary frequency. Grade 3 treatment-related adverse events occurred in 4%, and serious treatment-related adverse events in 2%, with no Grade 4 or Grade 5 events reported. Treatment-related adverse events led to treatment discontinuation and interruption in 1% and 4% of patients, respectively.
The submission timeline also needs to be understood separately. According to the company, the FDA meeting reached agreement on key aspects of the application, including the efficacy-evaluable population. enGene expects to begin submitting before year-end and to complete the application in the first half of 2027. This remains the company’s plan and does not mean that the FDA has accepted a complete application or agreed to approval. An update from another LEGEND cohort, in which a surfactant is used to rinse the bladder before dosing, is expected in mid-2027.
These data clarify detalimogene’s efficacy profile, while the limits of the evidence remain equally important. BioPharm International noted that the current results come from an interim analysis of an open-label, single-arm study and have not yet been peer reviewed. The lack of a randomized control group means that even if the figures are close to those of other approved therapies, cross-trial comparisons cannot establish superiority or inferiority. The outcomes most meaningful to patients—long-term disease control, the durability of bladder preservation, and the full safety profile—still await more mature data and regulatory review.